FDA approves BMS's (BMY.US) lung cancer drug repotrectinib.
According to reports, the FDA has approved the drug repotrectinib from Roche for the treatment of a type of non-small cell lung cancer.
According to reports, the FDA has approved Bristol-Myers Squibb's drug repotrectinib for the treatment of a type of non-small cell lung cancer. Media reported later on Wednesday that the drug has been approved. The agency accepted BMS's repotrectinib application in May. The pharmaceutical company is seeking approval for the use of the drug in the treatment of advanced or metastatic ROS1-positive non-small cell lung cancer. In 2022, BMS acquired Turning Point Therapeutics for $4.1 billion, thereby gaining access to the repotrectinib therapy.
Related Articles
Bengang Steel Plates (000761.SZ) plans to contribute in-kind assets such as its CCPP power generation assets to establish a wholly-owned subsidiary.
MNSO (09896) spent approximately US$238,600 to repurchase 108,800 shares on September 25.
(00625): Stabilization period ended; previously entered the market to purchase a total of 41.9985 million Class B shares
Bengang Steel Plates (000761.SZ) plans to contribute in-kind assets such as its CCPP power generation assets to establish a wholly-owned subsidiary.
MNSO (09896) spent approximately US$238,600 to repurchase 108,800 shares on September 25.
(00625): Stabilization period ended; previously entered the market to purchase a total of 41.9985 million Class B shares
